Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
83.70    1.60 (1.95%)
Bid:
83.10
Ask:
83.20
Spread: 0.10 (0.12%)
Market Cap: £137.22m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Appointment of Group Chief Executive

18 Nov 2014 07:00

RNS Number : 2005X
Synthomer PLC
18 November 2014
 



18th November 2014

 

Synthomer plc

 

Appointment of Group Chief Executive

 

Synthomer plc ('Synthomer' or 'the Company') is pleased to announce that it has appointed Calum MacLean as Group Chief Executive. Calum joins from INEOS Group ('INEOS'), where he is a senior Board executive and was a founder member of the business in 1998. He is currently Executive Chairman of INEOS Olefins and Polymers Europe.

 

Calum will join the Synthomer Board in early January 2015 and succeed Adrian Whitfield who announced in July that he would stand down after eight years as Chief Executive. Adrian will stay on to help with a handover process.

 

Calum is also Chairman of Styrolution, INEOS's joint venture with BASF, and Petroineos Refining, INEOS's joint venture with PetroChina. At INEOS, he has been Chief Executive of a number of its principal business units and actively involved in merger and acquisitions, strategy and implementation. Previously, he spent 6 years at Inspec (International Speciality Chemicals), a publicly listed company on the London Stock Exchange that was originally formed through a management buyout of BP Chemicals.

 

Neil Johnson, Chairman, said:

 

"Calum has an outstanding twenty year track record in the chemicals industry. His knowledge of our market and years of leadership experience will be invaluable in helping to take Synthomer into the next phase of its growth and development. We look forward to welcoming him to the business at the start of the New Year.

 

On behalf of the Board I would like to reiterate my thanks to Adrian Whitfield for his excellent contribution to Synthomer. Adrian has taken the business through substantial change, helping to redefine the business model alongside integrating a large and successful acquisition. He leaves Synthomer strategically well placed and financially strong and we wish him the very best for the future."

 

Calum MacLean said:

 

"Having spent nearly seventeen years at the heart of one of the UK's most successful chemical companies, I am enormously excited about a fresh challenge as Synthomer's new Chief Executive. The business offers exciting opportunities for future growth and I look forward to working with the team and taking the business forward."

 

 

There are no further details required to be disclosed under LR 9.6.13R of the Listing Rules of the UK Listing Authority.

 

Enquiries:

 

Pendomer Communications

+44 (0) 20 3603 5224

Charles Armitstead / Rebecca Hall

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEAFFXFSSLFFF
Date   Source Headline
26th Jun 20263:53 pmRNSDirector/PDMR Shareholding
22nd Jun 20261:31 pmRNSResults of AGM
22nd Jun 20267:00 amRNSAGM trading statement
19th Jun 20267:00 amRNSDivestment of Acrylate Monomers
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.